In summary, these data suggest that AML cells treated with the MDM2 inhibitor idasanutlin and the MEK1 inhibitor cobimetinib induced CDKN1A gene expression and cell cycle arrest, cell cycle exit and cell death, reduced levels of activated eIF4E protein, induced BAX gene expression, suppressed MCL1 gene expression, induced caspase3/7 activity and triggered apoptosis as summarized in Figure 4. The gene discussed is MAP2K1; the disease is acute myeloid leukemia.